Fig. 2From: Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraineMonthly response according to Month 1 migraine responsea category: (A) ≥75%, (B) 50–< 75%, (C) 25–< 50%, (D) < 25%. aMigraine response was defined as a percentage reduction in monthly migraine days. MRR, migraine responder rateBack to article page